Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2007

View Archived Issues

Takeda presents first quarter results for 2008

Cognition enhancement effects of A-412997, a D4 receptor agonist, reported

Canopus reports preclinical trials results of influenza antiviral drug StatC

Rectally delivered HIV vaccine immunogenic in preclinical studies

New treatment options for cardiovascular disorders disclosed in recent patents

Various types of novel oncolytic compounds described in recent patent literature

New agents for respiratory disorders disclosed in recent Japanese patent

Central effects of adiponectin on food intake elucidated

Bionomics to develop BNO69 inhibitors for cancer

FDA accepts Solvay's responses to approvable letters for Luvox CR and Luvox

Axcan Pharma submits complete NDA for Ultrase

Long-term use of Isotechnika's ISA-247 in phase IIb trial allowed by FDA

Unigene begins clinical study of oral calcitonin for osteoporosis

Update on Prana's phase IIa trial of PBT-2 for Alzheimer's disease

Hisamitsu acquires exclusive sales and distribution rights for Norspan for Japan

Patient enrollment for TorreyPines' phase IIb tezampanel trial completed

SkyePharma provides Flutiform progress update

Encysive files request for formal dispute resolution with FDA

Top-line results for MicroDose's glucose clamp study of QDose insulin inhaler

Anadis and ImmuCell sign heads of agreement for antibody technologies

Biovitrum and Wyeth to copromote BeneFIX in Nordic countries

Dynavax receives grant from NIAID to develop a universal flu vaccine

ImmuneRegen BioSciences finalizes material transfer agreement with VaxGen

New magnetic resonance imaging agent, a promising tool for Alzheimer's disease diagnosis

Betaseron treatment in the early phase of MS protects against confirmed disability

Archemix allies with Isis, SomaLogic for aptamer drug discovery and development

Novacta Biosystems receives funding for antiinfective agents for C. difficile

Tercica granted marketing approval for Increlex in the E.U.

Positive preclinical results from Quark's RNAi compound in acute renal failure

LEO Pharma enrolls first patient in phase II study of ATryn in DIC indication

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...